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How to End Selective Reporting in Ani mal Research 
Gerben ter Riet and Lex M. Bouter 
Basic research is like shooting an arrow in the air and, where it lands, 
painting a target. 
5.1 
lntrodu ction 
(Homer Adkins, Nature 1984} 
Would scientific progress not be a lot swifter and cheaper ifwe published, in some 
convenient format, all results from our negative studies too? Although convincing 
evidence is not available, we think the answer would be affirmative. New empiri-
ca! results appear daily, but it can sometimes take years for knowledge to emerge. 
Isolated studies may be important, but almost all deeper scientific insights evolve 
at the meta-level; that is, at the level of collections of similar studies around a par-
ticular scientific question. Since the 1980s, in clinical medicine and public health, 
systematic reviews (often including a meta-analysis) of the literature have been 
increasingly employed to produce ("meta-level") knowledge [l]. These systematic 
reviews ought to be updated when a new piece of evidence comes along. The cru-
cial role of integration of new findings with existing ones is not always appreciated 
in anima! experimental work, although its justification was eloquently expressed 
over a century ago: 
If, as is sometimes supposed, science consisted in nothing but the labori-
ous accumulation of facts, it would soon come to a standstill, crushed, as 
it were, under its own weight .... Two processes are thus at work side by 
si de, the reception of new material and the digestion and assimilation of the 
old ... The work which deserves, but I am afraid does not always receive, the 
most credit is that in which discovery and explanation go hand in hand, in 
which not only are new facts presented, but their relation to old ones is 
pointed out. [2] 
Timely updating of systematic reviews is needed as evidence keeps accumulat-
ing and, at some point, may change the overall picture [3]. The introduction of 
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systematic reviews has made the clinical scientific community aware that publica-
tion bias, the habit of not publishing negative or otherwise unwelcome results, 
thwarts truth finding and can lead to suboptimal healthcare [4]. It is plausible 
and there is also some evidence that large portions of the experimental anima! 
literature are also biased because of selective reporting practices [5]. The Collabo-
rative Approach to Meta-Analysis and Review of Anima! Data from Experimental 
Studies (CAMARADES collaboration) is an initiative that brings together data on 
anima! studies and meta-analyzes these where possible. It currently has centers in 
the UK, Australia, The Netherlands, the USA, and Canada [6] . lts remit is quite 
similar to that of the Cochrane and Camp bel! collaborations [7] . Non-publication 
of complete studies and selective reporting of only a proportion of their results 
are probably common. Intellectual or financial conflicts of interest along with the 
widespread misinterpretation and misuse of statistica! significance testing appear 
to be major drivers of selective reporting [8] . Non-publication of"negative" results 
logically implies that much wasteful replication occurs, that is, replication per-
formed inadvertently by investigators unaware of their repeated entry into sci-
entific cul-de-sacs [5c,9] . Conceptually, selective reporting can be viewed as a 
missing data problem at the meta-level [10]. Therefore, statistica! approaches help-
ful in detecting and repairing bias caused by non-randomly missing data might 
be relevant to counteract the distortions in the publicly available evidence base 
[11]. We believe, however, that selective reporting can and must be solved more 
fundamentally by smart redesign of the research processes [5b,12]. In the field 
of clinical trials, useful practices such as prospective trial registration, available 
since 2000 [13] and the promise-as of 2005-of the International Committee 
of Medica! Journal Editors (ICMJE) not to accept any trial-based manuscript for 
publication unless it has a trial registration number (TRN) [14] were clear sig-
nals that major stakeholders wanted to reduce selective reporting. However, it 
turned out to be difficult for investigators and editors to comply with these initia-
tives. More specifically, Mathieu and coworkers [15] found that, 5 years down the 
line, only 45.5% of randomized trials had been pre-registered as intended, and that 
unregistered trials had nevertheless been published in ICMJE journals. A recent 
report showed that again, 5 years on, this picture is essentially the same [16] . The 
US National Institutes of Health has now put in place more carrots and sticks 
to ensure compliance with the FDA Amendments Act, which requires sharing of 
summary data within 1 year after completion of data collection [17]. The ICMJE 
initiative aimed at 100% presence of a TRN for any trial published in an ICMJE-
associated journal. However, the more worthwhile goal is the publication of all 
trials ever performed [18]. Research has shown that in reality, the probability of 
encountering a TRN in ICMJE journals as wel! as the probability of a publica-
tion being given a TRN both !ie around a disappointing 50%, somewhat higher in 
non-government, non-industry trials, and lower in industry-sponsored trials [15, 
19]. Experimental anima! research may benefit from the experiences in the field of 
clinical trials, by copying and by improving procedures with a view to developing 
a watertight yet efficient system that prevents selective reporting and the ensuing 
biases in the aggregate literature [20] . 
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In this chapter, after reviewing evidence on magnitude, drivers, consequences 
of, and solutions to selective reporting, we argue that a future free of selective 
reporting can be achieved mainly through extending the tasks and jurisdiction 
of Institutional Anima! Care and Use Committees (IACUC) with comprehensive 
monitoring responsibilities and closer collaboration with sponsors. After all, 
no anima! experiment is allowed to start without ethics approval, making the 
IACUCs the ideal body to oversee which studies have reached their date of 
protocol-stipulated completion (21] . A smart and lean system of (electronic) 
monitoring of the progress of all anima! studies started combined with appropri-
ate sanctions could, in principle, put an end to selective reporting. It is a sobering 
thought that even if we were to end selective reporting practices tomorrow, 
bias in the publicly available evidence on all hypotheses that are not completely 
navel wil! only asymptotically approach zero as the existing, distorted evidence is 
mixed with new, unbiased, evidence. 
5.2 
Definition and Different Manifestations of Reporting Bias 
Reporting bias occurs if the probability of publication depends on the strength 
or direction of the results (22] . Thus, the spectrum runs from non-publication 
of complete studies to non-publication of a selection of the results. Put differ-
ently, if we define bias as systematic deviation from the truth, reporting bias 
occurs if the aggregated publicly available evidence (the "pooled estimate") on a 
particular parameter deviates from the truth because of non-random decisions 
to publish some research findings but not others. Reporting bias invalidates 
systematic reviews and meta-analyses and corrupts the cumulative scientific 
record. Reporting bias in clinical research may lead to errors in clinical practice 
guidelines and harm patients (23] . In anima! studies, reporting bias may cause 
needless replication attempts and may invite premature first-in-man studies. 
Reporting bias includes (i) publication bias where whole papers go missing, and 
(ii) parameter reporting bias where at least one, but not all, measured param-
eters (risk factor-outcome or intervention-outcome associations) go missing 
selectively. 
5.3 
Magnitude of Reporting Biases 
There are several ways to learn about the extent of reporting bias. Song et al. 
[22b] distinguished indirect and direct methods. Examples of indirect methods 
are comparison of the results of large and small studies or assessing the (gen-
erally very low) proportion of published studies that do not report any statis-
tically significant finding [8f,24]. Examples of direct methods are, for example, 
asking scientists [Sb,25] or comparing published and unpublished reports (26]. 
641 5 How to End Se/ective Reporting in Anima/ Research 
The follow-up of cohorts of study protocols is probably the most robust study 
design for learning about selective reporting. Possible starting points for follow-
up are (i) research protocols in the possession of IACUCs or Medica! Research 
Ethics Committees (MREC) or Institutional review Boards (IRB) as they are called 
in the USA, (ii) grant applications funded by funding bodies, (iii) entries into 
web-based trial registries such as clinicaltrials.gov, (iv) abstracts submitted to con-
ferences, and (v) research design papers, such as those published in the BMC 
series [27]. Reports of study results may be located through dedicated searches 
of bibliographical databases, such as, for example, Medline and EMBASE, inter-
net searches via Google Scholar, and through contact with researchers. We prefer 
taking approved submissions to IACUCs or IRBs as a starting point, since these 
contain the formally approved set of intended measurements that we re formulated 
closest to the date of commencement of studies, whereas plans offered to funding 
bodies may change after negotiations with sponsors or ethics committees. Follow-
up of such cohorts of research protocols has been clone for randomized clinical 
trials [22b,27], but to our knowledge not for anima! studies. 
Compared with the situation in randomized clinical trials, relatively little is 
known about the extent of reporting bias in experimental anima! research. What 
we do know are estimates derived from trim-and-fill analyses in the context of 
meta-analyses [Se] and a survey among anima! researchers [Sb] . ter Riet et al. 
[Sb], in an anonymous web-based survey among 4S4 Dutch anima! researchers, 
found that respondents believed that overall between 3S% and 70% of findings got 
published and that this was the case for 60- 90% of their own work. A subgroup of 
21 researchers working for-profit institutes thought that the publication rate was 
between S% and SO%, irrespective of whether it concerned their own work or that 
of others. Size of animals, seniority of researcher, and whether researchers were 
involved in fundamental research, preclinical research, or both hardly affected 
these estimates. Survey data on these types of sensitive issues obviously have their 
limitations. A PubMed search conducted on November 23 2014 located over 2S 
meta-analyses of anima! studies performed by the CAMARADES collaboration. 
These authors used the statistica! trim and .fill methodology to estimate and 
re pair funnel plot asymmetry [ 11 e] to estimate the relative overestimation of the 
pooled results in many of their meta-analyses. Across these meta-analyses we 
calculated a median value of the relative overestimation of intervention effects 
due to publication bias of 23% (interquartile range from 3 to 4S). Ina review of 16 
reviews comprising S2S anima! stroke studies, Sena et al. [Se], using trim and fill, 
estimated that 14% of studies had not been published. Imputing these missing 
studies lowered the pooled estimate of infarct size reduction across all studies 
from 31.3 to 23.8%. Tuis was equivalent toa 32% relative bias ((31.3 - 23.8) /23.8) . 
Note that the trim and fill method assumes that forest plot asymmetry is caused 
by publication bias, which need not be the case; other phenomena may account 
for (part of) the asymmetry as wel!. Song et al. warned that statistica! models 
to correct for publication bias should be interpreted cautiously: "all statistica! 
methods are by nature indirect and exploratory, and often based on certain strict 
assumptions that can be difficult to justify in the real world ... the attempt at 
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identifying or adjusting for publication bias in a systematic review should be 
mainly used for the purpose of sensitivity analyses" [22a]. 
5.4 
Consequences 
To set the scene, we give two examples of the potential harm caused by reporting 
bias in the area of human randomized trials . Then we will discuss what is known or 
may be postulated about consequences of reporting bias in experimental anima! 
research. 
5.4.1 
Consequences of Reporting Bias in Human Randomized Trials 
In 1980, a small randomized trial (N = 95) showing a 16.6% (p = 0.015) excess 
death rate in men who had a myocardial infarction and were prescribed the anti-
arrhythmic drug lorcainide was completed, but remained unpublished. In 1993, 
the authors, writing about their study, commented that: "It was designed to inves-
tigate the effect of lorcainide on arrhythmias, and was never intended to be large 
enough to allow any conclusions to be reached about an effect oflorcainide on sur-
vival. ... The development of lorcainide was abandoned for commercial reasons, 
and this study was therefore never published; it is now a good example of 'publi-
cation bias'. The results described here would have appeared before recruitment 
to the CAST Study began, and might have provided an early warning of trou-
ble ahead" [28). Instead of preventing cardiac arrhythmias, lorcainide appeared to 
trigger them. Only when the CAST trials, testing the drugs encainide, flecainide, 
and moracizine, in the late 1980s and early 1990s, reproduced these findings were 
these types of drug withdrawn from the market. In the meantime the number of 
US patients who had <lied prematurely due to anti-arrhythmia induced cardiac 
arrhythmias each year is estimated to be between 20 000 and 70 000. 
The Tamiflu (oseltamivir) story may serve as an example of massive eco-
nomie damage caused by publication bias [29). In 2008, a Cochrane review 
on Tamiflu showed the drug's effectiveness against complications of bird flu. 
Worldwide, developed countries spent billions of dollars (the exact amount 
is unknown) on stockpiling over 220 million treatments of Tamiflu to protect 
their populations in case of a bird flu pandemie. After an internet comment by 
a Japanese physician pointing out that the Cochrane review was mainly based 
on a manufacturer-sponsored meta-analytic summary of mostly unpublished 
data, a long struggle over making publicly available all the pertinent trial-based 
evidence ensued between the Cochrane reviewers and Roche, the manufacturer 
of Tamiflu [23). The 2014 version of this Cochrane review, which incorporates 
much more evidence, shows extremely modest effects of Tamiflu: "For the 
treatment of adults, oseltamivir reduced the time to first alleviation of symptoms 
by 16.8 h (p < 0.0001). Tuis represents a reduction in the time to first alleviation 
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of symptoms from 7 to 6.3 days .... Treatment of adults with oseltamivir had no 
significant effect on hospitalizations: risk difference (RD) 0.15% (95% Cl -0.78 
to 0.91) . Oseltamivir significantly reduced self-reported, investigator-mediated, 
unverified pneumonia (RD 1.00%, 95% Cl 0.22 to 1.49); number needed to treat 
to benefit= 100 (95% Cl 67 to 451) in the treated population. The effect was 
not significant in the five trials that used a more detailed diagnostic form for 
pneumonia. There were no definitions of pneumonia (or other complications) 
in any trial. No oseltamivir treatment studies reported effects on radiologically 
confirmed pneumonia" [30]. In this example, the economie damage caused by 
publication bias was enormous and the pharmaceutical industry's reputation was 
dealt another blow. 
5.4.2 
Consequences of Reporting Bias in Experimental Animal Research 
The grave consequences of selective reporting in clinical research are clear and a 
considerable number of horrific stories illustrate the pernicious chain from selec-
tively reporting positive findings, to a biased evidence base, to biased system-
atic reviews that then impact on clinical (treatment) guidelines finally resulting 
in flawed decisions in actual healthcare and sometimes massive loss of (quality 
adjusted) life years [31]. On the other hand, the consequences of selective report-
ing in anima! research are less well understood. To some extent this is caused by 
the fact that, generally speaking, to many people, the value of anima! research 
for human healthcare is less obvious than that of clinical research [9, 20, 32]. 
Nevertheless, the genera! issues are the same: redundancy, misguided follow-up 
research, and potential harm [33] . The bias that results from over-representation 
of positive findings (or negative findings when adverse effects are studied) distorts 
systematic reviews and meta-analyses and leads to overstatement of effective-
ness (and understatement of hann) [Se] . Furthermore, the animals used <lid not 
contribute to our aggregate knowledge base, and were therefore wasted [33] or 
played a minor role in some scientist 's personal learning curve. Needless repeats 
of studies are likely, although sometimes at conferences "rum or has it" that certain 
procedures do not work and at least some investigators know several of the scien-
tific cul-de-sacs and will avoid them. Based on distorted expectations, a decision 
to perform a first-in-man study may be taken incorrectly or prematurely [34]. And 
this may lead to useless clinical research that is a waste of resources and a potential 
risk for the participating patients. 
5.5 
Causes of Reporting Bias 
In an era where many researchers fee! pressurized to publish as many papers as 
possible, publication bias , in the sense that finished work is not even submit-
ted, seems paradoxical. There is some controversy over whether authors are to 
5.5 Causes of Reporting Bias 167 
be blamed for not submitting or reviewers and editors for blocking publication. 
There is research on the acceptance decisions of some journals showing that the 
journals are not to blame [35]. However, from our own experiences, we hypothe-
size that many scientists anticipate repeated rejections of "negative" results. The 
survey among anima! researchers by ter Riet et al. [5b] also seems to support this 
view. To the question "Who are responsible for non-publication in experimental 
anima! research?," respondents scored a median of 4 on a 5-point scale for the 
importance of editors, reviewers, and supervisors, whereas the option "lost inter-
est" scored low. Ina comprehensive review on the evidence of selective reporting, 
Song et al. take a balanced view and state that "The dissemination profile of a 
research finding is determined by the interests of research sponsors, investiga-
tors, peer-reviewers, and editors . . .. publication bias is often due to investigators' 
failure to write up and submit, although it should be recognized that the investiga-
tors' decision to write up an article and then submit it may be affected by pressure 
from research sponsors, preferences of journal editors, and the requirements of 
the research award system" [22b]. 
A useful distinction is that between financial and non-financial conflicts of 
interest. Conflicts of interest may play a role at the level of sponsors, scientists 
(including peer reviewers), and editors. Financial conflicts of interest and their role 
as drivers of reporting bias are easy to understand. Often, the non-financial con-
flicts of interest will involve pet theories or firmly held methodological beliefs [36]. 
Here we postulate a few human tendencies that are not always discussed, 
although they seem relevant in this context. We refer to our common tendency 
to seek novelty, good stories, and binary classifications as these tendencies may 
also help to explain the publication pressure - bias paradox. Let us present two 
of our beliefs. Firstly, people like good stories. Sad tales that only disprove the 
existence of phenomena do not generally stir our imagination [37], although 
we may occasionally devour a good story about icons who got it wrong. Until 
recently, one could still find journals whose instructions for authors stipulated 
that only findings that were novel or of a certain minimal magnitude would be 
considered for publication. The ultimate reasons behind this phenomenon are 
likely to be financial. In the end, even scientific journals are magazines that have 
to entertain their readers by publishing exciting (new) findings . They have a keen 
interest in improving their impact factor to keep attracting the "best" papers. 
After all, the publishers who run these journals are for-profit companies whose 
shareholders expect revenues produced by subscriptions and, increasingly, by 
publication fees. We have meta number of anima! researchers who explained that 
they tried to replicate published findings. However, it turned out that publication 
of replication studies is diffi.cult, since the perception may be that the research 
is not tackling something novel, is uncreative by only repeating what others did 
previously and successfully, or that an inability to obtain similar results may be 
explained by experimental ineptitude. It is hoped that the recent shock caused 
by a team of industry researchers who were able to replicate only six out 53 
published (anima!) studies even with help of the original investigators will change 
attitudes toward replication among cancer scientists [38] . 
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Secondly, medica! practitioners are uncomfortable with determinants that 
follow a continuous distribution. For example, most if not all cardiovascular risks 
are fairly smooth functions of, for example, blood pressure and serum cholesterol 
concentrations. In preventive cardiology, we know of no step functions where 
risks suddenly rise at some threshold value of a risk factor. This does not prohibit 
most medica! practitioners from acting on concepts such as hypotension and 
hypertension. Thirdly, most people are natura! Bayesians. That is, they have a 
belief; they encounter new evidence, (critically) appraise it, and after assimilating 
it their updated belief lies somewhere between the old belief and that which 
the new evidence supports. Thus, depending on the strength of the initia! belief 
and the amount of fresh evidence, gradual shifts in belief seem natura! [39]. 
However, in the planning and the statistica! evaluation of scientific studies, most 
researchers seem to abandon this natura! Bayesian inclination. The sample size 
dogma in essence means that each single experiment by itself should convince 
everyone irrespective of their initia! beliefs [40]. And the evaluation of the 
evidence, although quantified as a p-value on a continuous scale between 0 and 
l, is dichotomized, just like serum cholesterol, into a "Yes, the phenomenon 
exists" or an "Aw, the study results are negative." Steven Goodman, in an eloquent 
paper, describes how in the l 930s, Sir Ronald Fis her invented the p-value as qui te 
an informal measure of inference that was to replace its competitors, namely, 
hypothesis testing [sic!] and Bayesian methods [Sa,b,41]. The modern marriage 
between the p-value and significance testing would have Fisher turning in his 
grave. Although this issue of the possibility of expressing the evidentiary value 
of a study into a single number is subtle and complicated, Figure 5.1, based 
on fictitious data, shows how rigid binary p-value thinking may lead to absurd 
conclusions about the compatibility of study results. Two studies are pictured 
that were claimed to be contradictory in the sense that the study by Smith was 
negative whereas that by Jones was positive. The graph shows that bath are in 
full agreement about the treatment effect (RR = 0.78), but that their precision 
is different due to different sample sizes of 20 and 2000, respectively. The graph 
clearly shows the compatibility of these results. However, "concise" binary 
reporting of the results of these two trials (see last column), omitting a graph or 




In this section, we will discuss some methods proposed to counteract selective 
reporting. Tuis section ends with a proposal for ensuring complete publication. 
The idea of submitting to journals manuscripts from which the results section 
was omitted was first launched in 1970 [42]. Editors and peer reviewers would 
judge the importance of manuscripts using solely the background, the hypotheses 
and study objectives, and methods sections. If convinced that the objectives were 
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Author Year P _Value 
Smith 2012 NS 
Jones 2014 p<.05 
Overall 
.2 .5 2 5 
Faveurs treatment Faveurs control 
Relative Risk 
NS = not significant 
Figure 5.1 Forest plot showing that contra-
diction of two trial results in terms of sta-
tistica! significance is fully compatible with 
exact agreement of their estimated effect 
size. Here the trials by Smith and Jones both 
measured a preventive treatment effect of 
0.778 relative to control. A huge sample size 
difference explains the seeming contradiction 
when a rigid significance testing paradigm is 
applied. 
worth pursuing and the methods appropriate, a document would be signed that 
was close to a guarantee of publication irrespective of the nature of the results. 
The next version of the manuscript would then be complete with tables, figures, 
and other material to describe the results. Such a procedure would ensure that 
acceptance was not conditional on the nature of the findings. We are not aware of 
journals that experimented with or adopted this system. Why wouldn't they? The 
cynical view, of course, is the one we gave earlier: scientific journals are ultimately 
magazines striving to entertain their readership, with publishers and a commercial 
market system operating in the background. Let us explore the potential additional 
administrative burden of the proposal as compared to the current system, where 
we include the results in the first submission (Table 5.1). 
We see that under fairly standard scenarios, the proposed new system is asso-
ciated with a minor amount of additional administration. Given the deleterious 
effects on science caused by reporting bias, we strongly recommend the proposed 
system. Ideally, the decision to adopt a system of publication should be based 
on cost-effectiveness considerations, explicitly from a societal perspective. We 
believe that the costs of reporting bias are huge and can easily justify some addi-
tional expenditure in the handling of manuscripts. 
Other measures that are currently in place to some extent include special jour-
nals, journal sections, or repositories for "negative" results, such as the fournal 
of Negative Results in Biomedicine and The All Results fournals [43]. In addition, 
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Table 5.1 Additional administrative steps for editors in a system in which the initial submis-
sion contains no results. 
Current system (manuscript contains results 
directly; 10-16 steps) 
1. Receive manuscript 
2. Decide on straight rejection, if not, then 
3. Assign reviewers 
4. Remind reviewers (mostly automated) 
5. Collect reviewers' comments 
6. Discuss with co-editors, statistician 
7. Summarize and correspond with authors 
8. Receive resubmission 
9. Forward to reviewers 
10. Remind reviewers (mostly automated) 
ll. Collect reviewers' comments 
12. Discuss with co-editors, statistician 
13. Summarize and correspond with authors 
14. Receive final manuscript 
15. Posting or printing procedures 
16. Post-publication activities (letters, etc.) 
Proposed system (objective and methods 
are approved directly; 14-21 steps) 
Receive manuscript without results 
Decide on straight rejection, if not, then 
Assign reviewers 
Remind reviewers (mostly automated) 
Collect reviewers' comments 
Discuss with co-editors, statistician 
Summarize and correspond with authors 
Receive resubmission (naw with results) 
Forward to reviewers 
Remind reviewers (mostly automated) 
Collect reviewers' comments 
Discuss with co-editors, statistician 
Summarize and correspond with authors 
(Repeat steps 6-10 if results section <lid 
not match step 1) 
Posting or printing procedures 
Post-publication activities (letters, etc.) 
the fournal of Cerebral Blood Flow and Metabolism and Neurobiology of Aging 
feature Negative Results sections with a similar flavor [43b,44). The fournal of 
Cerebral Blood Flow and Metabolism describes this section as follows: "The Neg-
ative Results section of the Journal of Cerebral Blood Flow and Metabolism wil! 
provide a platform and raise awareness of a problem with a proven negative impact 
on scientific progress as well as bench-to-bedside translation. Now researchers 
must step up to this platform. It is an experiment, but, if successful, it may serve 
as a role model for other journals and other research fields and thus help to reduce 
publication bias" [44a]. 
Since statistica! insignificance is probably a main cause of non-publication, its 
dogmatic use should be discouraged. Tuis may be difficult, however. In our expe-
rience, even medica! students in their first year already seem indoctrinated with 
the idea that findings should preferably be statistically significant. 
There are a few other plausible candidate solutions to the problem of selec-
tive reporting. We mention prospective registration, separate publication of study 
protocols [45), data sharing, and enhanced carrot and stick approaches by fund-
ing bodies [46]. All these are incorporated in the proposal we will sketch below. 
Figure 5.2 shows our proposal for the organization of scientific (anima!) research 
seeking to eradicate selective reporting. Our proposal is an attempt to integrate 
different ideas that were launched previously into one coherent system [33, 47). 
Tuis system has four key components: (i) early end-user input, (ii) systematic 
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Figure 5.2 Flow chart depicting a system 
designed to reduce research waste and 
reporting bias. Note that animalresearch.gov 
is a non-existing website used to illustrate 
preregistration of all animal studies. lts name 
was inspired by clinicaltrials.gov, the US-
based website for preregistration of (random-
ized) clinical trials. 
Tuis scheme was inspired by the procedures used by the UK HTA program, which 
succeeds in having 98% of funded research published [46a,48]. Let us take you 
through Figure 5.2 and clarify some of its components . Horizontally, the black 
bar on top shows four activities: the first phase is the conception of ideas and the 
second systematic review of the relevant literature, a process that also continues 
through the third phase, the conduct of the primary research project. The final and 
fourth phase is the reporting of study results . The process starts on the left-hand 
side, with the box indicated by the yellow label and number 1. A new research 
idea emerges, potentially developed with help of end-users, which in the case of 
OIJ 
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anima! research may be clinicians or translational specialists or even patients . 
To comply with strict funders' requirements, a scoping search of the literature 
is conducted to study the available evidence on the hypothesis at issue, to pre-
vent needless replication, and to learn from predecessors' successes and mistakes. 
lf at least one good and recent systematic review exists, the simplest route goes 
via box 3 to box 8 and a research proposal is written, submitted for funding (box 
9, notice the end-users' influence on the funding decisions (blue arrow)), and if 
obtained, IACUC approval is sought (box 10). lfthe IACUC approves the protocol 
it sends the protocol to animalresearch.gov, where its contents are automatically 
checked for completeness against an authoritative guideline for protocols using 
natura! language processing [49]. The study is conducted (box 11, which allows 
for IACUC-approved amendments of the protocol at animalresearch.gov during 
conduct) and the IACUC monitors progress and reporting. Reporting, which is 
much more comprehensive than in the current system, has three components: 
(i) the report is submitted to animalresearch.gov (box 6.1) and checked for com-
pleteness against the ARRIVE guidelines (see Section 3.1) for complete reporting 
using natura! language programming software; (ii) the raw data, the cleaned data, 
and carefully annotated statistica! cleaning and analysis syntaxes are submitted 
to the funder and put in an open access repository with informative meta-data 
to allow checks and re-use of data for secondary analyses including individual 
anima! meta-analyses (box 7.1); and (iii) irrespective of submissions to animal-
research.gov, researchers wil! still be allowed to publish (an abbreviated) version 
of their work in a scientific journal under an open access system of publication. 
Entries in animalresearch.gov wil! contain hyperlinks to all open access publi-
cations about the study. End-users may access reports via the outlets described 
above (box 7.1). So the sequence of boxes 10-6.1-11 [6.1]- 7.1-13 is fixed just 
like the sequence of boxes 1 and 2. Some variation enters the protocol if a good 
and recent systematic review is not found and has to be written or updated with 
its own protocols and reports. 
There are some key differences from the current system. The extent of reporting 
is not the only difference. Note how the funders, using their carrot and stick 
approach, such as withholding 10-20% of funds unless the requirements for 
reporting are met, are supposed to cooperate closely with the IACUCs as illus-
trated by the thick blue lines. The fund ers are the natura! guardians of the data and 
the syntaxes, since they will eventually receive future submissions for secondary 
research on existing data. The IACUCs wil! have an active monitoring role, 
chasing up researchers who do not deliver within a reasonable time frame. Not 
delivering without good reasons may lower the chances of subsequent funding 
because IACUCs and funders cooperate closely and share information. Finally, 
the academie reward system should also reflect the system depicted in Figure 5.2. 
lnstead of focusing solely on publications and citations, researchers must also be 
rewarded for the secondary use of their data sets and/or syntaxes and deployment 
of their work by the end-users. loannidis and Khoury [50] have recently proposed 
the PQRST (P = productive, Q = high-quality, R = reproducible, S = shareable, 
and T = translatable) reward system to replace the current system, which is 
References 
gauged too much toward counting publications and citations. The reward system 
for scientists is a key element in making our proposal work, since the current 
high level of competitiveness in science works against pre-registration of research 
ideas. A key element in the system described here is the fully automated checks of 
study protocols and study report manuscripts submitted to animalresearch.gov. 
The sheer numbers of submissions require this. The interplay between the 
submitted texts and the natura! language-processing software based on the 
guidelines for study protocols and reporting needs to be robust for the system 
to work appropriately. On the other hand, given the large sums of money 
wasted in the current system [33,47b,51], the necessary investments in the more 
sophisticated approach we describe here are likely to make sense. For research 
that has no explicit funding or projects that fail completely, perhaps due to 
technica! or personnel problems, we hope that a reward system along the lines 
of the PQRST system will motivate scientists to pre-register projects and submit 
brief summaries of the reasons why a project may have failed completely. It will 
by now be abundantly clear that by "failed," we do not refer to the nature of the 
study results in any way. 
In conclusion, selective reporting in clinical research has immense costs in 
terms of money and health. The economie and scientific impact of selective 
reporting in anima! research is an under-researched topic but is likely to be 
considerable as wel!. lncreasingly, incomplete reporting of research outcomes is 
seen as a form of research misconduct, and more attention is being paid to the 
wasteful aspects of our current system of doing science. The initiatives originating 
in the clinical field have great potential to improve the state of affairs in anima! 
research as wel!. 
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